80242-24-6

Basic information

• Product Name: 4-Cyano-1H-pyrrole-2-carboxylic acid
• Synonyms: 4-Cyano-1H-pyrrole-2-carboxylic acid;4-Cyanopyrrole-2-carboxylic acid;2-Carboxy-4-cyano-1H-pyrrole, 5-Carboxy-1H-pyrrole-3-carbonitrile;4-Cyano-1H-pyrrole-2-carboxylic acid 97+%
• CAS NO: 80242-24-6
• Molecular Formula: C₆H₄N₂O₂
• Molecular Weight: 136.11
• Mol File: 80242-24-6.mol
• Article Data: 7

Chemical Properties

• Melting Point: 279℃ (decomposition)
• Boiling Point: 416.865°C at 760 mmHg
• Flash Point: 205.913°C
• Appearance: /
• Density: 1.503g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.613
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-Cyano-1H-pyrrole-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Cyano-1H-pyrrole-2-carboxylic acid(80242-24-6)
• EPA Substance Registry System: 4-Cyano-1H-pyrrole-2-carboxylic acid(80242-24-6)

Safety Data

• Hazardous Substances Data: 80242-24-6(Hazardous Substances Data)

Usage

General Description

4-Cyano-1H-pyrrole-2-carboxylic acid is a chemical compound with the molecular formula C7H4N2O2. It falls under the category of organoheterocyclic compounds, specifically a pyrrole subcategory, which are cyclic compounds containing at least one atom of an element other than carbon (in this case, nitrogen), and at least one carbon atom. 4-Cyano-1H-pyrrole-2-carboxylic acid displays a notable reactivity due to the strength of the N-H bond and the electron deficiency of the carbon atom of the pyrrole ring. In a chemical context, it is mainly used in the field of pharmaceuticals and as a synthesis intermediate. It is generally used as a building block in the organic synthesis of a variety of other chemical compounds. In the context of safety and handling, the compound should be handled with care as it may cause skin and eye irritation with direct exposure.

InChI:InChI=1/C6H4N2O2/c7-2-4-1-5(6(9)10)8-3-4/h1,3,8H,(H,9,10)

Upstream product

• 80242-23-5 trichloroacetyl-(4-cyano-1H-pyrrol-2-yl) 
• 35302-72-8 pyrrol-2-yl trichloromethyl ketone 

Downstream Products

• 124-38-9 carbon dioxide 
• 7126-38-7 pyrrole-3-carbonitrile 
• 885704-89-2 tert-butyl 4-(4-(4-cyano-1H-pyrrole-2-carboxamido)-3-(4-methylpiperidin-1-yl)phenyl)piperazine-1-carboxylate 
• 885704-21-2 4-cyano-N-(4-(4-methylpiperazin-1-yl)-2-(4-methylpiperidin-1-yl)phenyl)-1H-pyrrole-2-carboxamide 

Relevant articles and documents

METHOD OF INHIBITING C-KIT KINASE

A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.

INHIBITORS OF C-FMS KINASE

The invention is directed to compounds of Formula (I): wherein A, X, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula (I), are also provided.

SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR

The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from compounds of Formula I′: Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.